Oct 10, 2003

SynChem (China), Ltd established its new laboratory in Shanghai, China.

SynChem (China), Ltd, a branch company of Chicago-based SynChem, Inc, established its new 12,500 sq. ft. laboratory in Shanghai, China. This expands the facility to a total of 25,000 sq. ft. and is fully equipped and functional laboratory capable of production to kilogram scale. By combining its Chicago-based laboratory and Shanghai-based laboratory SynChem can offer its full spectrum service to its customers, ranging from time-sensitive projects to cost-sensitive projects. Through integration of its two sites SynChem continues its commitment to become a powerhouse in an organic synthesis for its customers, including drug discovery, biotech, and pharmaceutical companies.

June 20, 2003

SynChem, Inc. and Helicon Therapeutics, Inc. sign collaborative research agreement for process research chemistry

Helicon Therapeutics, Inc. and SynChem, Inc. today announced that they have signed an agreement for the process research chemistry for one of Helicon’s development compounds. Under the terms of the agreement, SynChem will combine its expertise in the organic synthesis with Helicon’s proprietary drug lead for the treatment of disorders of cognitive function related to memory. Both companies will contribute unique, chemical expertise to the Collaboration. Helicon has a research program based on CREB activation, which serve as target for the identification of novel therapeutics for memory loss. "We are delighted to initiate this process research chemistry collaboration with Helicon. We look forward to achieving success on behalf of Helicon and growing our company with Helicon whom we can provide this very valuable organic chemistry service” said Dr. W. Paul Mar, President and CEO of SynChem, Inc. “We are pleased to work with SynChem on this project. They will make unique contributions to the scale-up of the synthesis and advancement of this candidate”, said John Tallman, Ph.D., President and CEO of Helicon Therapeutics.

About Helicon Therapeutics

HELICON THERAPEUTICS INC. is a pioneer in the development of therapies for memory-related disorders. Helicon, founded in 1997, is a privately held Company formed to understand the genetic basis of long-term memory formation and discover therapeutics to treat disorders of cognition. The scientific foundation and intellectual property of Helicon originated in the neuroscience program at the Cold Spring Harbor Laboratory. Helicon has developed technologies that can identify genes involved in memory formation, and identify and develop drugs that influence those genes that enhance memory and cognitive function. Its principal shareholders are Cold Spring Harbor Laboratory, OSI Pharmaceuticals, and institutional and private investors in Europe and the United States. For more information, please visit www.helicontherapeutics.com

SynChem, Inc. is a privately held contract research organization providing research services in all aspects of organic chemistry. SynChem complements the experience of its researchers with proprietary tools in organic chemistry and combinatorial chemistry building blocks. For more information, please visit www.synchem.com. selected as one of Eli Lilly and Company's 2002 Supplier Award winners! There are 18 award winners for this year's suppliers throughout Lilly, including four in its research division. SynChem's representatives attended the awards presentation on August 8, 2002.